{"version":"1.0","provider_name":"GenomeFrontier Therapeutics, Inc. \u5148\u9a45\u751f\u6280","provider_url":"https:\/\/genomefrontier.com\/zh","author_name":"GenomeFrontier","author_url":"https:\/\/genomefrontier.com\/zh\/author\/admingf\/","title":"Taiwan FDA clears GenomeFrontier\u2019s IND application for GF-CART01, a CD20\/CD19 dual targeting CAR T cell therapy for hematological B cell malignancies! - GenomeFrontier Therapeutics, Inc. \u5148\u9a45\u751f\u6280","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"txSsb0nPF9\"><a href=\"https:\/\/genomefrontier.com\/zh\/portfolio-item\/news031\/\">\u53f0\u7063\u98df\u85e5\u7f72(TFDA)\u5df2\u6838\u51c6\u5148\u9a45\u751f\u6280\u63d0\u4ea4\u7684GF-CART01\u81e8\u5e8a\u8a66\u9a57\u7533\u8acb(IND)\uff0c\u8a72\u7642\u6cd5\u70ba\u91dd\u5c0d\u8840\u6db2\u578bB\u7d30\u80de\u60e1\u6027\u816b\u7624\u7684CD20\/CD19\u96d9\u6a19\u9776CAR-T\u7d30\u80de\u6cbb\u7642\uff01\n\n\u53f0\u7063\u98df\u54c1\u85e5\u7269\u7ba1\u7406\u7f72\uff08TFDA\uff09\u6838\u51c6\u5148\u9a45\u751f\u6280\u4e4b GF-CART01\u65b0\u85e5\u81e8\u5e8a\u8a66\u9a57\u7533\u8acb(IND)\u3002\u8a72\u7642\u6cd5\u70ba\u4e00\u6b3e\u540c\u6642\u9776\u5411CD20\/CD19\u7684\u96d9\u6a19CAR-T\u7d30\u80de\u6cbb\u7642\uff0c\u9069\u7528\u65bc\u8840\u6db2\u6027 B \u7d30\u80de\u60e1\u6027\u816b\u7624\uff01<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/genomefrontier.com\/zh\/portfolio-item\/news031\/embed\/#?secret=txSsb0nPF9\" width=\"600\" height=\"338\" title=\"Taiwan FDA clears GenomeFrontier\u2019s IND application for GF-CART01, a CD20\/CD19 dual targeting CAR T cell therapy for hematological B cell malignancies! &#8212; GenomeFrontier Therapeutics, Inc. \u5148\u9a45\u751f\u6280\" data-secret=\"txSsb0nPF9\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/* ]]> *\/\n<\/script>"}